sur MONOGRAM ORTHOPAEDICS INC (NASDAQ:MGRM)
Monogram Technologies Secures Initial Strategic Clinical Trial Collaboration
Monogram Technologies Inc. has announced a strategic collaboration with Shalby Limited to conduct a multicenter clinical trial. This follows the successful 510(k) submission and FDA Administrative Review for the mBÈs TKA System. Shalby, a global leader in orthopedic surgeries, will enroll patients at various sites in India to evaluate the system's safety and effectiveness.
Shalby, which performs over 14,000 knee replacement surgeries annually, represents around 15% of the arthroplasty market in India. Under this collaboration, Shalby will use the Consensus CKS implant, equivalent to Monogram's mPress implants for regulatory purposes. The trial includes the potential post-trial transfer of a robot to Shalby under specific conditions.
Monogram's CEO, Ben Sexson, emphasized the significant market potential in India for robotics, while Dr. Vikram Shah, Chairman of Shalby, expressed enthusiasm about the partnership and the transformative potential of Monogram's technology.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de MONOGRAM ORTHOPAEDICS INC